Novo Nordisk

Novo Nordisk A/S is a Danish multinational pharmaceutical company. It is one of the leaders in pharmaceutical products and services, particularly in the treatment of diabetes. Its headquarters are located in Bugswehr, a suburb of Copenhagen.
Novo Nordisk stock price chart
vol.
change
P/E
Net profit
P/B
Book value
Debts
Net debt
Yield
Growth potential

Novo Nordisk balance sheet

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Capitalization, kr.
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Novo Nordisk cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Novo Nordisk multipliers

Report period2017 2018 2019 2020 2021 2022
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Novo Nordisk profitability

Report period2017 2018 2019 2020 2021 2022
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Novo Nordisk assets
Novo Nordisk cash flows
Novo Nordisk dividends
0%

Novo Nordisk dividend policy

The company pays dividends once every six months

Novo Nordisk shares

TickerNameTypeNominal valueISINPrice
NVO:USNovo Nordisk A/SDepositary receipt-US6701002056$122.7
Novo Nordisk news
04.02.2022
Novo Nordisk's board of directors has proposed a final dividend for 2021 of DKK 6.9 per share, or approximately $1.05 per depositary receipt. The last day to buy the securities to receive the dividend is March 24, 2022. The dividend yield could be 1.54%.
Source: {source} pictogram ml-eu.globenewswire.com
Pictogram next
04.02.2022
Novo Nordisk's IFRS net income for 2021 amounted to kr.47.757 billion, up 13.3% from kr.42.138 billion in the previous year. Revenue increased by 10.9% to kr.140.8 billion compared to kr.126.946 billion a year earlier.
Source: {source} pictogram ml-eu.globenewswire.com
Pictogram next
28.12.2021
Novo Nordisk has completed its acquisition of Dicerna Pharmaceuticals. The company develops mRNA-based drugs and also owns a technology platform to access intracellular disease targets in hepatic and extrahepatic cells and tissues. Novo Nordisk paid $3.3 billion, or $38.25 per Dicerna share.
Source: {source} pictogram novonordisk.com
Pictogram next
18.11.2021
Novo Nordisk acquires Dicerna Pharmaceuticals, which develops mRNA-based drugs. The company also owns a technology platform to access intracellular disease targets in hepatic and extrahepatic cells and tissues. Novo Nordisk will pay $3.3 billion, or $38.25 per Dicerna share. The deal is scheduled to close in Q4 2021.
Source: {source} pictogram novonordisk.com
Pictogram next
All Novo Nordisk news
General information
Company nameNovo Nordisk
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business addressNOVO ALLE DK 2880 BAGSVAERD DENMARK G7 00000 4544448888
Mailing addressNOVO ALLE DK 2880 BAGSVAERD DENMARK G7 00000
Websitewww.novonordisk.com